Navigation Links
Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
Date:9/1/2013

AMSTERDAM, The Netherlands and OSAKA, Japan, Sept. 2, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) today announced results of the EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial, showing the primary endpoint of non-inferiority compared to placebo in addition to standard of care was met with no increase in CV risk in a Type 2 diabetes patient population at high-risk for CV events. These data, published in the New England Journal of Medicine (NEJM) and also presented at the ESC Congress 2013, demonstrate that alogliptin does not increase CV risk in Type 2 diabetes patients at high-risk for major adverse cardiac events (MACE) due to a recent acute coronary syndrome (ACS). The trial's primary objective was to evaluate non-inferiority of CV risk based on a primary composite endpoint of CV death, nonfatal myocardial infarction and nonfatal stroke. The primary endpoint occurred at similar rates in the alogliptin and placebo groups (in 11.3% of patients vs. 11.8% of patients during a median follow-up period of 18 months; hazard ratio, 0.96; one-sided repeated confidence interval [CI] bound, 1.16). Alogliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4i) for the treatment of Type 2 diabetes in adults to improve glycemic control as an adjunct to diet and exercise.

"There is a need for safer glucose lowering therapies in patients with diabetes who are at an elevated risk for cardiovascular disease," stated William B. White, MD, FASH, FAHA, FACP, principal investigator of the EXAMINE trial. "Given the EXAMINE study design and high-risk patient population evaluated, these results provide key insights to clinicians treating diabetes patients with coronary disease."

The global EXAMINE trial is an im
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
2. Takeda Launches New Subsidiary in Peru
3. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
4. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
5. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
6. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
7. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
8. Takeda to Acquire Inviragen, Inc.
9. Takeda Responds to Verdict in Diabetes Drug Case
10. Takeda Launches New Subsidiary in Ecuador
11. Takeda lanza nueva subsidiaria en Ecuador
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... gefragt. Das Problem dabei ist, dass ... mit der Kompetenz zu teilen. Es ... deshalb freuen wir uns umso mehr, dass es ... ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit einem ...
(Date:10/17/2014)... , Oct. 17, 2014 With ... Medical Affairs function has come across several challenges ... efficiently and managing globalization.  The ... LLC is dedicated to providing benchmarking and best ... Affairs Consortium is a service composed of three ...
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... 27 Due to rising patient responsibility for ... state laws requiring disclosure of information on hospital charges, ... estimates for healthcare services. Competitive hospitals also realize they ... accountability to key stakeholders, protect against compliance risks, focus ...
... , , ... 280,000 external defibrillators used worldwide in health care facilities, public places, or in the home ... Drug Administration warned today. , , , ... , , , ...
Cached Medicine Technology:Craneware Shares Patient Estimation Revenue Integrity Insights 2Craneware Shares Patient Estimation Revenue Integrity Insights 3Craneware Shares Patient Estimation Revenue Integrity Insights 4FDA Warns Users About Faulty Components in 14 External Defibrillator Models 2FDA Warns Users About Faulty Components in 14 External Defibrillator Models 3
(Date:10/20/2014)... Kennewick, WA (PRWEB) October 20, 2014 ... new workflow management software application. The new module ... ensure patients receive full life-cycle quality care. , This ... to others within their practice, attach a to-do item ... see fit, and even set up reoccurring reminders for ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
(Date:10/20/2014)... 20, 2014 It’s hard to imagine what ... and vulnerable children around the world, it’s a reality. And ... many children are forced to walk barefoot on rocky terrain ... or play with their friends. , Buckner International's ... Air1 Radio in October to encourage support for Air1 ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... Recently, Top10BestSEOHosting.com has unveiled its newest ... and HostMonster are the best VPS hosting suppliers ... is the method of partitioning a physical server ... the appearance and capabilities of running on someone’s ... pays close attention to VPS products and related ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2
... suffering from posttraumatic stress disorder (PTSD) are as likely ... disease risk factors such as an elevated white blood ... healthcare providers screen for PTSD in the same way ... , Exposure to trauma has not only psychological effects, ...
... Name ... Same Commitment to ... the Health of all Babies, CINCINNATI, Feb. ... that 4-year-old Bradley,Coffey of Kennedy Heights and his family will serve as ... WalkAmerica,March for Babies is the March of Dimes premier fundraising event that,benefits ...
... /PRNewswire-FirstCall/ - LMS Medical Systems (TSX:,LMZ, AMEX: LMZ), ... information system and risk management software tools for,obstetrics, ... third,quarter ended December 31, 2007. All amounts are ... new installations and growing recurring maintenance,and technical service ...
... Briefing on Feb. 12, WASHINGTON, Feb. ... a significant role in preparing federal legislation,received ... groups. The American Society of Transplantation (AST), ... Organ Sharing (UNOS),and Association of Organ Procurement ...
... (Nasdaq: DYNT ) will release financial results ... February 14, 2008., Dynatronics has scheduled a ... p.m. ET to discuss its results for the ... should call 800-839-9416 and use,passcode: 1383812., Dynatronics ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that ... Mid-Cap Growth Conference on Friday, February 15,2008 at approximately ... is scheduled to be webcast live and may be ... . The webcast will,be available for 30 days following ...
Cached Medicine News:Health News:Geisinger study: PTSD a medical warning sign for long-term health problems 2Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 2Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 3Health News:LMS Third Quarter 2008 Financial Results - Q3 Revenue Increases 88% to $1.0 Million - YTD Revenue Increases 87% to $2.6 Million 2Health News:LMS Third Quarter 2008 Financial Results - Q3 Revenue Increases 88% to $1.0 Million - YTD Revenue Increases 87% to $2.6 Million 3Health News:LMS Third Quarter 2008 Financial Results - Q3 Revenue Increases 88% to $1.0 Million - YTD Revenue Increases 87% to $2.6 Million 4Health News:Transplant Community Unites to Educate Capitol Hill Staffers About the 'Gift of Life' 2Health News:Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference 2
Hatsis tying forceps, titanium, long thin tying platforms....
Gills Colibri forceps, very fine pointed tips....
Fine tying forceps, curved tips, wide handle....
Castroviejo tying forceps, tying platforms, straight, 0.3 mm teeth....
Medicine Products: